Rice GPA, Hartung HP, Calabresi PA (2005) Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64(8):1336–1342. https://doi.org/10.1212/01.WNL.0000158329.30470.D0

Article  CAS  PubMed  Google Scholar 

Butzkueven H, Kappos L, Wiendl H et al (2020) Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri observational program (TOP). J Neurol Neurosurg Psychiatry 91(6):660–668. https://doi.org/10.1136/jnnp-2019-322326

Article  PubMed  Google Scholar 

Miller DH, Khan OA, Sheremata WA et al (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348(1):15–23. https://doi.org/10.1056/NEJMoa020696

Article  CAS  PubMed  Google Scholar 

Foley JF, Goelz S, Hoyt T, Christensen A, Metzger RR (2019) Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing. Mult Scler Relat Disord 31:65–71. https://doi.org/10.1016/j.msard.2019.03.017

Article  PubMed  Google Scholar 

van Kempen ZLE, Hoogervorst ELJ, Wattjes MP et al (2020) Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial. Neurology 95(6):e745–e754. https://doi.org/10.1212/WNL.0000000000009995

Article  CAS  PubMed  Google Scholar 

Zhovtis Ryerson L, Frohman TC, Foley J et al (2016) Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry 87(8):885–889. https://doi.org/10.1136/jnnp-2015-312940

Article  CAS  PubMed  Google Scholar 

De Mercanti SF, Signori A, Cordioli C et al (2021) MRI activity and extended interval of natalizumab dosing regimen: a multicentre Italian study. J Neurol Sci 424:117385. https://doi.org/10.1016/j.jns.2021.117385

Article  CAS  PubMed  Google Scholar 

Foley JF, Defer G, Ryerson LZ et al (2022) Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol 21(7):608–619. https://doi.org/10.1016/S1474-4422(22)00143-0

Article  CAS  PubMed  Google Scholar 

Ratchford JN, Brock-Simmons R, Augsburger A et al (2014) Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle. Int J MS Care 16(2):92–98. https://doi.org/10.7224/1537-2073.2013-017

Article  PubMed  PubMed Central  Google Scholar 

Bringeland GH, Blaser N, Myhr KM, Vedeler CA, Gavasso S (2020) Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy. Neurol Neuroimmunol Neuroinflammation 7(3):e678. https://doi.org/10.1212/NXI.0000000000000678

Article  Google Scholar 

Bringeland GH, Blaser N, Myhr KM, Vedeler CA, Gavasso S (2021) Wearing-off symptoms during standard and extended natalizumab dosing intervals: experiences from the COVID-19 pandemic. J Neurol Sci 429:117622. https://doi.org/10.1016/j.jns.2021.117622

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goretti B, Patti F, Cilia S et al (2014) The Rao’s brief repeatable battery version B: normative values with age, education and gender corrections in an Italian population. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 35(1):79–82. https://doi.org/10.1007/s10072-013-1558-7

Article  CAS  Google Scholar 

Pisa M, Chieffo R, Congiu M et al (2021) Intracortical motor conduction is associated with hand dexterity in progressive multiple sclerosis. Mult Scler Houndmills Basingstoke Engl 27(8):1222–1229. https://doi.org/10.1177/1352458520960374

Article  Google Scholar 

Stampanoni Bassi M, Mori F, Buttari F et al (2017) Neurophysiology of synaptic functioning in multiple sclerosis. Clin Neurophysiol Off J Int Fed Clin Neurophysiol 128(7):1148–1157. https://doi.org/10.1016/j.clinph.2017.04.006

Article  Google Scholar 

Di Lazzaro V, Rothwell J, Capogna M (2018) Noninvasive stimulation of the human brain: activation of multiple cortical circuits. Neurosci Rev J Bringing Neurobiol Neurol Psychiatry 24(3):246–260. https://doi.org/10.1177/1073858417717660

Article  Google Scholar 

Nantes JC, Zhong J, Holmes SA, Narayanan S, Lapierre Y, Koski L (2016) Cortical damage and disability in multiple sclerosis: relation to intracortical Inhibition and facilitation. Brain Stimulat 9(4):566–573. https://doi.org/10.1016/j.brs.2016.01.003

Article  Google Scholar 

Hupfeld KE, Swanson CW, Fling BW, Seidler RD (2020) TMS-induced silent periods: A review of methods and call for consistency. J Neurosci Methods 346:108950. https://doi.org/10.1016/j.jneumeth.2020.108950

Article  CAS  PubMed  PubMed Central  Google Scholar 

Franciotta D, Zardini E, Bergamaschi R, Andreoni L, Cosi V (2003) Interferon gamma and Interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing Immunomodulatory treatment. J Neurol Neurosurg Psychiatry 74(1):123–126. https://doi.org/10.1136/jnnp.74.1.123

Article  CAS  PubMed  PubMed Central  Google Scholar 

Learmonth YC, Dlugonski D, Pilutti LA, Sandroff BM, Klaren R, Motl RW (2013) Psychometric properties of the fatigue severity scale and the modified fatigue impact scale. J Neurol Sci 331(1):102–107. https://doi.org/10.1016/j.jns.2013.05.023

Article  CAS  PubMed  Google Scholar 

O’Connor P, Goodman A, Kappos L et al (2014) Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS study. Neurology 83(1):78–86. https://doi.org/10.1212/WNL.0000000000000541

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yeh WZ, Widyastuti PA, Van der Walt A et al (2021) Natalizumab, Fingolimod and dimethyl fumarate use and Pregnancy-Related relapse and disability in women with multiple sclerosis. Neurology 96(24):e2989–e3002. https://doi.org/10.1212/WNL.0000000000012084

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ryerson LZ, Foley J, Kister I et al (2023) Natalizumab extended interval dosing (EID) is associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) compared with Every-4-Week (Q4W) dosing: updated analysis of the TOUCH® prescribing program database (P14-3.011). Neurology 100(17supplement2):1598. https://doi.org/10.1212/WNL.0000000000202006

Article  Google Scholar 

Ryerson LZ, Foley J, Chang I et al (2019) Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology 93(15):e1452–e1462. https://doi.org/10.1212/WNL.0000000000008243

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dalla Costa G, Leocani L, Pisa M et al (2024) Neuroaxonal damage in natalizumab-treated MS patients: the role of JCV antibody titres. Mult scler Houndmills Basingstoke engl. Published Online June 14:13524585241260977. https://doi.org/10.1177/13524585241260977

Article  CAS  Google Scholar 

Kivisäkk P, Healy BC, Viglietta V et al (2009) Natalizumab treatment is associated with peripheral sequestration of Proinflammatory T cells. Neurology 72(22):1922–1930. https://doi.org/10.1212/WNL.0b013e3181a8266f

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cathérine D, Annelien DP, Anne S et al (2020) End of dose interval symptoms in patients treated with natalizumab: A role for serum cytokines? Mult Scler Relat Disord 41:102020. https://doi.org/10.1016/j.msard.2020.102020

Article  PubMed  Google Scholar 

Mori F, Nisticò R, Nicoletti CG et al (2016) RANTES correlates with inflammatory activity and synaptic excitability in multiple sclerosis. Mult Scler Houndmills Basingstoke Engl 22(11):1405–1412. https://doi.org/10.1177/1352458515621796

Article  CAS  Google Scholar 

Rossi S, Studer V, Motta C et al (2012) Inflammation inhibits GABA transmission in multiple sclerosis. Mult Scler Houndmills Basingstoke Engl 18(11):1633–1635. https://doi.org/10.1177/1352458512440207

Article  CAS  Google Scholar 

Vezzani A, Viviani B (2015) Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability. Neuropharmacology 96(Pt A):70–82. https://doi.org/10.1016/j.neuropharm.2014.10.027

Article  CAS